The Board of Directors of IGC Pharma, Inc. approved a change in the company’s fiscal year end on December 30 2025, with the new period ending on December 31 2025. The shift aligns the company’s reporting calendar with the standard U.S. calendar year, a move intended to improve transparency and comparability for investors.
To accommodate the change, IGC Pharma will file a transition Form 10‑K covering the nine‑month period from April 1 2025 through December 31 2025. The first full calendar‑year report will be filed in 2026, providing a seamless transition for analysts and shareholders.
The decision reflects the company’s focus on advancing its AI‑driven Alzheimer’s program and its need to communicate more clearly with U.S. investors. CEO Ram Mukunda said, “Aligning our fiscal year with the calendar year improves clarity, comparability, and accessibility of our financial reporting as we continue to advance our clinical and AI‑driven programs.”
Financial context underscores the timing of the change. In the third quarter of FY2025, IGC Pharma generated revenue of $191,000 and recorded a net loss of $1.821 million. For the full FY2025, revenue was $1.27 million, a 5.5% decline from the prior year, while the net loss narrowed to $7.1 million from $13 million in FY2024. Cash and equivalents stood at $1.105 million as of September 30 2025. The company remains in a loss‑making phase but has recently raised capital, completing a $234 k direct offering on January 5 2026.
The fiscal year‑end shift is a routine governance change but is material because it alters the reporting cadence and enhances comparability with peers. No significant market reaction is expected beyond routine analyst updates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.